

Company registration number: 365044

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31ST DECEMBER 2022

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

Company information

Directors	Desmond Crowley Esmonde Keane Donal Ryan Marie-Josée Leclerc Aine Tyers Anita Whyte - (Resigned 04/08/2022) Denis Ryan - (Appointed 26/05/2022) Liz Pigott-Glynn - (Appointed 26/05/2022)
Secretary	Donal Ryan
Company number	365044
Registered office	33 Manor Street Dublin 7
Business address	33 Manor Street Dublin 7
Auditor	Hayden Brown Grafton Buildings 34 Grafton Street Dublin 2
Bankers	Bank of Ireland Smithfield Dublin 7

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

Contents

	Page
Directors report	1 - 2
Directors responsibilities statement	3
Independent auditor's report to the members	4 - 6
Income and expenditure account	7
Balance sheet	8
Statement of changes in reserves	9
Statement of cash flows	10
Notes to the financial statements	11 - 20

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**DIRECTORS REPORT
YEAR ENDED 31ST DECEMBER 2022**

The directors present their report and the financial statements of the company for the year ended 31st December 2022.

Directors

The names of the persons who at any time during the financial year were directors of the company are as follows:

Desmond Crowley
Esmonde Keane
Donal Ryan
Marie-Josée Leclerc
Aine Tyers
Anita Whyte - (Resigned 04/08/2022)
Denis Ryan - (Appointed 26/05/2022)
Liz Pigott-Glynn - (Appointed 26/05/2022)

Principal activities

The principle activity of the company is to assist people who are involved in drug-taking and / or prostitution by offering them support and guidance in their efforts to rehabilitate and to help them to overcome their addictions.

Development and performance

The surplus for the year after providing for depreciation amounted to €31,871 (2021 surplus - €15,702). Funding received was spent for the purposes which it had been granted. The surplus for the year will be utilised in future periods under the terms of the grants received.

Future developments

The directors are not expecting to make any significant changes in the nature of the business in the near future. At the time of approving the financial statements, the company is exposed to the effects of the Covid-19 pandemic which has had a negative effect on its activities since the year end and has resulted in increased work demands and corresponding costs. In planning its future activities, the directors will seek to develop the company's activities whilst managing the effects of the difficult trading period caused by this outbreak.

Principal risks and uncertainties

The principle risk and uncertainty affecting Chrysalis Community Drug Project CLG for the year ahead is the reduction in funding from government grants which the company receives and the affects this will have on the ongoing operations of the organisation. The directors have instituted measures to ensure that costs are reduced in line with future funding streams.

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**DIRECTORS REPORT (CONTINUED)
YEAR ENDED 31ST DECEMBER 2022**

Going Concern

The company is dependent on income provided from government funders. As with many government funded organisations, the company is affected by both budgetary constraints implemented by the national government and external economic restraints. The directors have reviewed all relevant information and are confident that the company has adequate financial resources to continue in operational existence for the foreseeable future. Consequently, the directors consider it appropriate to prepare the financial statements on a going concern basis.

Taxation Status

The company, as a charity (CHY no. 16902, CRA no. 20061944), is not liable to corporation tax under section 207 (as applied to companies by section 76) of the Taxes Consolidation Act, 1997.

Events after the end of the reporting period

There have been no significant events affecting the company since the financial year-end.

Accounting records

The measures taken by the directors to secure compliance with the requirements of sections 281 to 285 of the Companies Act 2014 with regard to the keeping of accounting records are the implementation of necessary policies and procedures for recording transactions, the employment of competent accounting personnel with appropriate expertise and the provision of adequate resources to the financial function. The accounting records of the company are located at 33 Manor Street, Dublin 7.

Relevant audit information

In the case of each of the persons who are directors at the time this report is approved in accordance with section 332 of Companies Act 2014:

- so far as each director is aware, there is no relevant audit information of which the company's statutory auditors are unaware, and
- each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's statutory auditors are aware of that information.


Compliance

Chrysalis Community Drug Project CLG is compliant with relevant circulars including Circular: 44/2006 "Tax Clearance Procedures Grants, subsidies and Similar Type Payments" and DPE 022/05/2013 Circular: 13/2014 'Management of and Accountability for Grants from Exchequer Funds'.

Auditors

The auditors, Hayden Brown, have indicated their willingness to continue in office in accordance with the provisions of Section 383(2) of the Companies Act 2014.

This report was approved by the board of directors on 1st June 2023 and signed on behalf of the board by:



Esmonde Keane
Director



Donal Ryan
Director

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**DIRECTORS RESPONSIBILITIES STATEMENT
YEAR ENDED 31ST DECEMBER 2022**

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law, the directors have elected to prepare the financial statements in accordance with Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council, and promulgated by the Institute of Chartered Accountants in Ireland. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors confirm that they have complied with the above requirements in preparing the financial statements.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.



Esmonde Keane
Director

Donal Ryan
Director

1st June 2023

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF
CHRYSALIS COMMUNITY DRUG PROJECT CLG (CONTINUED)
YEAR ENDED 31ST DECEMBER 2022**

Report on the audit of the financial statements

Opinion

We have audited the financial statements of Chrysalis Community Drug Project CLG for the year ended 31st December 2022 which comprise the Income and Expenditure Account, balance sheet, statement of changes in reserves, statement of cash flows and notes to the financial statements, including a summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish law and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland.

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31st December 2022 and of its surplus for the year then ended;
- have been properly prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland; and
- have been prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the responsibilities section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and the provisions available for small entities, in the circumstances set out in note 17 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report

Other Information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF
CHRYSALIS COMMUNITY DRUG PROJECT CLG (CONTINUED)
YEAR ENDED 31ST DECEMBER 2022**

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2014

Based solely on the work undertaken in the course of the audit, we report that:

- in our opinion, the information given in the directors' report is consistent with the financial statements; and
- in our opinion, the directors' report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which we consider necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited, and financial statements are in agreement with the accounting records.

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions required by sections 305 to 312 of the Act are not made. We have nothing to report in this regard.

Respective responsibilities

Responsibilities of directors for the financial statements

As explained more fully in the directors responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF
CHRYSALIS COMMUNITY DRUG PROJECT CLG (CONTINUED)
YEAR ENDED 31ST DECEMBER 2022**


As part of an audit in accordance with ISAs (Ireland), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.


Ciaran Murray

For and on behalf of
Hayden Brown
Chartered Accountants and Registered Auditors
Grafton Buildings
34 Grafton Street
Dublin 2

1st June 2023

CHRYSLIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)

INCOME AND EXPENDITURE ACCOUNT
YEAR ENDED 31ST DECEMBER 2022

	Note	2022 €	2021 €
Income		985,016	912,111
Gross income		<u>985,016</u>	<u>912,111</u>
Administrative expenses		(953,145)	(896,409)
Surplus for the financial year	6	<u>31,871</u>	<u>15,702</u>

All the activities of the company are from continuing operations.

The company has no other recognised items of income and expenses other than the results for the year as set out above.

The financial statements were approved by the board of directors on 1st June 2023 and signed on behalf of the board by:


Esmonde Keane
Director


Donal Ryan
Director

The notes on pages 11 to 20 form part of these financial statements.

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**BALANCE SHEET
31ST DECEMBER 2022**

	Note	2022 €	€	2021 €	€
Fixed assets					
Tangible assets	8	6,909		-	
			6,909		-
Current assets					
Debtors	9	7,408		19,140	
Cash at bank and in hand		282,269		200,198	
		289,677		219,338	
Creditors: amounts falling due within one year	10	(159,448)		(117,526)	
Net current assets			130,229		101,812
Total assets less current liabilities			137,138		101,812
Creditors: amounts falling due after more than one year	11		(3,455)		-
Net assets			133,683		101,812
Reserves					
Income and Expenditure account	14		133,683		101,812
Members funds			133,683		101,812

These financial statements were approved by the board of directors on 1st June 2023 and signed on behalf of the board by:


Esmonde Keane
Director


Donal Ryan
Director

The notes on pages 11 to 20 form part of these financial statements.

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**STATEMENT OF CHANGES IN RESERVES
YEAR ENDED 31ST DECEMBER 2022**

	Income and Expenditure account €	Total €
At 1st January 2021	86,110	86,110
Surplus for the year	15,702	15,702
Total comprehensive results for the year	15,702	15,702
At 31st December 2021	101,812	101,812
Surplus for the year	31,871	31,871
Total comprehensive results for the year	31,871	31,871
At 31st December 2022	133,683	133,683

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**STATEMENT OF CASH FLOWS
YEAR ENDED 31ST DECEMBER 2022**

	2022	2021
	€	€
Cash flows from operating activities		
Surplus for the financial year	31,871	15,702
<i>Adjustments for:</i>		
Depreciation of tangible assets	3,455	-
Accrued expenses/(income)	(2,494)	2,335
<i>Changes in:</i>		
Trade and other debtors	11,732	(13,789)
Trade and other creditors	47,871	40,721
Cash generated from operations	<u>92,435</u>	<u>44,969</u>
Net cash from operating activities	<u>92,435</u>	<u>44,969</u>
Cash flows from investing activities		
Purchase of tangible assets	(10,364)	-
Net cash (used in)/from investing activities	<u>(10,364)</u>	<u>-</u>
Net increase/(decrease) in cash and cash equivalents	82,071	44,969
Cash and cash equivalents at beginning of year	<u>200,198</u>	<u>155,229</u>
Cash and cash equivalents at end of year	<u>282,269</u>	<u>200,198</u>

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31ST DECEMBER 2022**

1. Statement of compliance

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

2. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements have been prepared in accordance with FRS 102 and with Irish law comprising of the Companies Act 2014.

The financial statements are prepared in Euros, which is the functional currency of the entity.

Income

Income is accounted for when amounts receivable on grants and funding applications are paid.

Voluntary Income: Voluntary income is recognised in the period in which the organisation is entitled to the resource, receipt is virtually certain and when the amount can be measured with sufficient reliability.

Restricted Income: Income received by the organisation, the application of which is restricted to a specific purpose by the donor, is treated as restricted income and any unspent amounts as restricted assets. Such specified purposes are within the overall aims of the organisation.

Unrestricted Income: Other income, apart from restricted income, is used by the organisation in the furtherance of its work and objectives. Such funds may be held in order to finance working capital or may be used at the discretion of the organisation for specified purposes that are within the aims of the organisation.

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31ST DECEMBER 2022**

Tangible assets

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Computer equipment	- 33.33% straight line
Fixtures, fittings and equipment	- 20% straight line

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31ST DECEMBER 2022**

Government grants

Government grants are recognised at the fair value of the asset received or receivable. Grants are not recognised until there is reasonable assurance that the company will comply with the conditions attaching to them and the grants will be received.

Government grants are recognised using the accrual model and the performance model.

Under the accrual model, government grants relating to revenue are recognised on a systematic basis over the periods in which the company recognises the related costs for which the grant is intended to compensate. Grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the entity with no future related costs are recognised in income in the period in which it becomes receivable.

Grants relating to assets are recognised in income on a systematic basis over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income and not deducted from the carrying amount of the asset.

Under the performance model, where the grant does not impose specified future performance-related conditions on the recipient, it is recognised in income when the grant proceeds are received or receivable. Where the grant does impose specified future performance-related conditions on the recipient, it is recognised in income only when the performance-related conditions have been met. Where grants received are prior to satisfying the revenue recognition criteria, they are recognised as a liability.

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31ST DECEMBER 2022**

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in income or expenditure. All other such investments are subsequently measured at cost less impairment.

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31ST DECEMBER 2022**

3. Critical Judgements and Estimates

The preparation of these financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenditure.

Judgements and estimates are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The charity makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

(a) Establishing useful economic life for depreciation purpose

The annual depreciation charge depends primarily on the estimated useful economic lives of each type of asset and estimate of residual value. The directors regularly review these assets useful lives in light of prospective economic utilisation and physical condition of the assets concerned. Changes in asset useful lives can have a significant impact on depreciation charges for the period. Detail of the useful economic lives is included in the accounting policies.

(b) Going concern

The directors have prepared budgets for the next financial year which demonstrate that there is no material uncertainty regarding the company's ability to meet its liabilities as they fall due, and to continue as a going concern. On this basis the directors consider it appropriate to prepare the financial statements on a going concern basis. Accordingly, these financial statements do not include any adjustments to the carrying amounts and classification of assets and liabilities that may arise if the company were unable to continue as a going concern.

4. Limited by guarantee

The liability of the members is limited. In the event of the Company being wound up each member undertakes to contribute towards the payment of any debts and liabilities of the Company. Any such contribution by each member is limited to €1.

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31ST DECEMBER 2022**

5.	Grant Agency	Sponsoring Government Department	Purpose of Fund	Term of Grant	2022 €
	North Inner City Drug and Alcohol Task Force	Department of Health	Note A	1 year	310,095
	North East Inner City	Department of Health	Note B	1 year	651,382
	HSE	Department of Health	Note C	1 year	371
	HSE	Department of Health	Note D	1 year	6,172
	HSE	Department of Health	Note E	1 year	4,846
	HSE	Department of Health	Note F	1 year	12,000

Note

- A Annual fixed contribution towards the costs of employing a specified number of full time equivalent positions.
- B NEIC development fund grant for the staff in the Inner City Hub who work along side City Clinic and the Inner City Community.
- C €8,800 National Lottery grant awarded in 2021 for upgrading IT systems and Intercom system. The grant was not fully spent in 2021 and €6,450 was carried forwards and spent in 2022. Part of the grant was spent on capital items in 2022 and deferred as a capital grant.
- D €6,172 National Lottery grant awarded for the company's project "improvement of health and safety requirements." The grant was received in November 2021 and was not spent in the year. The grant was carried forwards and spent in 2022.
- E €8,000 National Lottery grant was awarded for the company's project - 4 training courses. The grant was not fully spent in 2022 and €3,154 was deferred into 2023.
- F Mental Health Ireland administered a €16,000 grant on behalf of the Department of Health / HSE for the delivery of 3 external mental health training for the overall teams. The grant was not fully spent in 2022. €4,000 was deferred into 2023.

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31ST DECEMBER 2022**

6. Surplus

Surplus is stated after charging/(crediting):

	2022	2021
	€	€
Depreciation of tangible assets	3,455	-
	<u>3,455</u>	<u>-</u>

7. Staff costs

The average number of persons employed by the company during the year was as follows:

	2022	2021
	Number	Number
Core Staff	21	20
	<u>21</u>	<u>20</u>

The aggregate payroll costs incurred during the year were:

	2022	2021
	€	€
Wages and salaries	718,706	665,518
Social insurance costs	78,525	72,890
	<u>797,231</u>	<u>738,408</u>

The Charity had one employee whose total employee benefits for the reporting period exceeds €60,000 as detailed below.

	2022	2021
	€	€
€70,000 to €80,000	1	-
€60,000 to €70,000	-	1
	<u>1</u>	<u>1</u>

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31ST DECEMBER 2022**

8. Tangible assets

	Computer equipment	Fixtures, fittings and equipment	Total
	€	€	€
Cost			
At 1st January 2022	8,340	6,916	15,256
Additions	10,364	-	10,364
At 31st December 2022	<u>18,704</u>	<u>6,916</u>	<u>25,620</u>
Depreciation			
At 1st January 2022	8,340	6,916	15,256
Charge for the year	3,455	-	3,455
At 31st December 2022	<u>11,795</u>	<u>6,916</u>	<u>18,711</u>
Carrying amount			
At 31st December 2022	<u>6,909</u>	<u>-</u>	<u>6,909</u>
Carrying amount			
At 31st December 2021	<u>-</u>	<u>-</u>	<u>-</u>

9. Debtors

	2022	2021
	€	€
Other debtors	-	430
Prepayments	7,408	18,710
	<u>7,408</u>	<u>19,140</u>

10. Creditors: amounts falling due within one year

	2022	2021
	€	€
Trade creditors	7,049	1,625
Other creditors	-	44
Tax and social insurance:		
PAYE and social welfare	18,036	16,044
Accruals	5,910	8,404
Government grants	128,453	91,409
	<u>159,448</u>	<u>117,526</u>

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31ST DECEMBER 2022**

11. Creditors: amounts falling due after more than one year

	2022	2021
	€	€
Government grants	3,455	-
	<u>3,455</u>	<u>-</u>

12. Government grants

	2022	2021
	€	€
As at the start of the year	91,409	54,039
Grants received or receivable	1,028,820	949,361
Released to the income or expenditure	(988,321)	(911,991)
As at the end of the year	<u>131,908</u>	<u>91,409</u>

The amounts recognised in the financial statements for government grants are as follows:

	2022	2021
	€	€
Recognised in creditors:		
Government grants due within one year	128,453	91,409
Government grants due after more than one year	3,455	-
	<u>131,908</u>	<u>91,409</u>

13. Financial instruments

The carrying amount for each category of financial instruments is as follows:

	2022	2021
	€	€
Financial assets that are debt instruments measured at amortised cost		
Cash at bank and in hand	<u>282,269</u>	<u>200,198</u>
Financial liabilities measured at amortised cost		
Trade creditors	<u>(7,049)</u>	<u>(1,625)</u>

14. Reserves

The company has one class of reserves as follows:

Income and expenditure account:

This reserve records retained earnings and accumulated losses.

**CHRYSALIS COMMUNITY DRUG PROJECT CLG
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
YEAR ENDED 31ST DECEMBER 2022**

15. Events after the end of the reporting period

There have been no significant events affecting the company since the financial year-end.

16. Related party transactions

On the 1st July 2022 the company entered into a lease agreement to rent the ground and first floor offices at 32 Manor Street, Dublin 7 from Malson Holdings Limited. The lease agreement is for a period of three years. The lease will end on the 30th June 2025. The rent was agreed at €26,000 per annum. Malson Holdings Limited is a company ultimately owned by Donal Ryan, Director and Secretary of Chrysalis Community Drug Project CLG. For the period 1st July 2022 to the 31st December 2022 €13,000 in rent was paid to Malson Holdings Limited. No monies were owed to / (owed by) Malson Holdings at the 31st December 2022. Donal Ryan abstained completely in his capacity as director from the decision making process with regard to the lease agreement. Chrysalis Community Drug Project CLG directors engaged the services of a suitably qualified professional valuer to carry out an independent valuation of the property.

17. Ethical standard - provisions available for small entities

In common with many other businesses of our size and nature we use our auditors to prepare and assist with the preparation of the financial statements. We also use our auditors to provide tax advice and to represent us, as necessary, at tax tribunals.

18. Controlling party

The members of the company are the controlling party.

19. Approval of financial statements

The board of directors approved these financial statements for issue on 1st June 2023.

